11/8/26 One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Previous Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Next Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors You Might Also Like Retention by Design - Keeping Families Engaged for Multi-Year Studies From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients.
11/8/26 One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Previous Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Next Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors You Might Also Like Retention by Design - Keeping Families Engaged for Multi-Year Studies From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients.
